Recent Updates
Recently added Catalysts

JNJ-38431055

Phase 1

Diabetes Mellitus, Type 2 | Small molecule | Metabolic |Johnson & Johnson|Last Updated: Sep 4, 2013

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials2
Total Enrollment55
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01054118A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and SitagliptinPHASE1 COMPLETED 18Dec 1, 2009Feb 1, 2010Sep 4, 20131 United States
NCT00910923A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-38431055 in Healthy Male VolunteersPHASE1 COMPLETED 37Nov 1, 2008Apr 1, 2009Oct 6, 2009 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
GLP-1 levels after a standard meal
0-4 hours after the standard meal
To assess the safety and tolerability of JNJ-38431055
Secondary Endpoints
To evaluate the pharmacokinetics of JNJ-38431055 administered alone and in combination with sitagliptin.
24 hours after dosing
Assess the effect of JNJ-38431055 on appetite and satiety using a visual analogue scale (VAS)
Within 24 hours of dosing
Assess the safety and tolerability of JNJ-38431055 administered alone and in combination with sitagliptin as measured by occurrence of adverse events, ECGs, vital signs, and safety laboratory measurements.
From screening visit through follow-up visit
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
001EXPERIMENTALJNJ-38431055 Liquid suspension of JNJ-38431055 administered as a single dose
002ACTIVE_COMPARATORSitagliptin 100 mg Capsule containing 100 mg of sitagliptin administered as a single dose
003EXPERIMENTALJNJ-38431055 + Sitagliptin 100 mg Liquid suspension of JNJ-38431055 administered as a single dose and capsule containing 100 mg of sitagliptin administered as a single dose
004PLACEBO_COMPARATORPlacebo Placebo suspension and placebo capsule administered as single doses
Interventions
NameTypeDescription
JNJ-38431055DRUGLiquid suspension of JNJ-38431055 administered as a single dose
Sitagliptin 100 mgDRUGCapsule containing 100 mg of sitagliptin administered as a single dose
JNJ-38431055 + Sitagliptin 100 mgDRUGLiquid suspension of JNJ-38431055 administered as a single dose, and capsule containing 100 mg of sitagliptin administered as a single dose
PlaceboDRUGPlacebo suspension and placebo capsule administered as single doses
Unlock Study Design Details
Eligibility Criteria
Age Range19 Years — 55 Years
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Body Mass Index (BMI) between 27.0 and 38.0 kg/m2 (inclusive) * Healthy on the basis of physical examination including medical history, vital signs, 12-lead ECG, and all other screening lab tests * Men must agree to use a double barrier method of birth control (e.g., condom fo...

Countries:United States
Unlock Eligibility Criteria